178 related articles for article (PubMed ID: 37410236)
1. Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-muscle-Invasive Bladder Cancer.
Ecke TH; Benderska-Söder N; Bismarck E; van Rhijn BWG; Todenhöfer T; Schmitz-Dräger BJ
Methods Mol Biol; 2023; 2684():199-212. PubMed ID: 37410236
[TBL] [Abstract][Full Text] [Related]
2. Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
Benderska-Söder N; Ecke T; Kleinlein L; Roghmann F; Bismarck E; van Rhijn BWG; Stenzl A; Witjes JA; Todenhöfer T; Hakenberg OW; Grimm MO; Goebell PJ; Burger M; Jensen JB; Schmitz-Dräger BJ
Urol Oncol; 2024 Aug; 42(8):229-235. PubMed ID: 38403529
[TBL] [Abstract][Full Text] [Related]
3. Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer.
Feiertag N; Barry E; Abramson M; Park JY; Kovac E; Aboumohamed A; Watts K; Sankin A
Clin Genitourin Cancer; 2023 Apr; 21(2):258-264. PubMed ID: 36621462
[TBL] [Abstract][Full Text] [Related]
4. Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker.
Rouprêt M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Longo F; Montanari E; Palou J; Sylvester RJ
Eur Urol Focus; 2022 Nov; 8(6):1643-1649. PubMed ID: 35300937
[TBL] [Abstract][Full Text] [Related]
5. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
6. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
7. Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial.
Benderska-Söder N; Hovanec J; Pesch B; Goebell PJ; Roghmann F; Noldus J; Rabinovich J; Wichert K; Gleichenhagen J; Käfferlein HU; Köhler CU; Johnen G; Kernig K; Hakenberg O; Jahn D; Todenhöfer T; Stenzl A; Gleissner J; Gerwert K; El-Mashtoly S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2020 Dec; 38(12):886-895. PubMed ID: 32199755
[TBL] [Abstract][Full Text] [Related]
8. Can urinary biomarkers replace cystoscopy?
Maas M; Bedke J; Stenzl A; Todenhöfer T
World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995
[TBL] [Abstract][Full Text] [Related]
9. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
[TBL] [Abstract][Full Text] [Related]
10. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project.
Hurle R; Casale P; Saita A; Colombo P; Elefante GM; Lughezzani G; Fasulo V; Paciotti M; Domanico L; Bevilacqua G; Maffei D; Diana P; Frego N; Sandri MT; Maura F; Morenghi E; Buffi NM; Guazzoni G; Lazzeri M
World J Urol; 2020 Sep; 38(9):2215-2220. PubMed ID: 31691083
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
[TBL] [Abstract][Full Text] [Related]
12. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
13. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
[TBL] [Abstract][Full Text] [Related]
14. Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients.
Montalbo R; Lozano JJ; Izquierdo L; Ingelmo-Torres M; BaÑos C; Palou J; Van der Heijden AG; Medina R; Schmidbauer J; Prat A; Ribal MJ; Alcaraz A; Mengual L
Transl Res; 2019 Jun; 208():73-84. PubMed ID: 30771285
[TBL] [Abstract][Full Text] [Related]
15. Current concepts of tumor markers in bladder cancer.
Droller MJ
Urol Clin North Am; 2002 Feb; 29(1):229-34. PubMed ID: 12109349
[TBL] [Abstract][Full Text] [Related]
16. Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.
Hekman MCH; Wijn SRW; Lotan Y; Govers TM; Witjes JA
World J Urol; 2023 Feb; 41(2):471-476. PubMed ID: 36534153
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial.
Cochetti G; Rossi de Vermandois JA; Maulà V; Cari L; Cagnani R; Suvieri C; Balducci PM; Paladini A; Del Zingaro M; Nocentini G; Mearini E
Urol Oncol; 2022 Mar; 40(3):105.e11-105.e18. PubMed ID: 34911649
[TBL] [Abstract][Full Text] [Related]
18. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
19. Alternatives to cytology in the management of non-muscle invasive bladder cancer.
Amiel GE; Shu T; Lerner SP
Curr Treat Options Oncol; 2004 Oct; 5(5):377-89. PubMed ID: 15341676
[TBL] [Abstract][Full Text] [Related]
20. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.
Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Aufderklamm S; Böttge J; Rausch S; Mischinger J; Bier S; Gakis G; Kuehs U; Stenzl A; Schwentner C
Dis Markers; 2014; 2014():973406. PubMed ID: 25587206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
